FectoVIR®-AAV, a giant step for AAV large scale manufacturing

Learn more with our expert!
View webinar

FectoVIR-AAV, a giant step for AAV large scale manufacturing

AAVs are the most promising viral vector for gene therapy thanks to their broad tropism and non-integrating properties. The current challenge is manufacturing sufficient amount of recombinant AAVs (rAAVs) viral particles to treat patients. In order to improve productivity, viral manufacturers are working on optimising their upstream process to produce higher amounts of rAAVs by switching to more performant cell suspension systems and transient transfection systems that can be scaled-up for industrial manufacturing. During this webinar, we will demonstrate how our novel transfection reagent FectoVIR-AAV is developped for large scale transient transfection of suspension cell systems to produce higher reproducible amounts of rAAVs.

 

Presentation by 
Alengo NYAMAY'ANTU, PhD
Scientific Communication Specialist
Polyplus-transfection®
an@polyplus-transfection.com

Duration
15 minutes

You can view this webinar from your computer, tablet or mobile phone.

Share this webinar